Novel Cytocompatible Chitosan Schiff Base Derivative as a Potent Antibacterial, Antidiabetic, and Anticancer Agent

Abstract This study intends to develop a novel bioactive chitosan Schiff base (CTS-SB) derivative via coupling of (CTS) with 4-((5, 5-dimethyl-3-oxocyclohex-1-en-1-yl) amino) benzene-sulfonamide. The alteration in the chemical structure CTS-SB was verified using 1 H NMR and FT-IR analysis, while thermal morphological properties were inspected by TGA SEM characterization tools, respectively. Ion exchange capacity developed recorded maximal value 12.1 meq/g compared 10.1 for pristine CTS. In addition, antibacterial activity greatly boosted against Escherichia coli ( E ) Staphylococcus aureus S. bacteria. Minimum inhibition concentration perceived at 50 µg/mL, highest (250 µg/mL) could inhibit growth up 91%. What’s more, enhanced antidiabetic derivative, which displayed higher inhibitory values α-amylase (57.9%) α-glucosidase (63.9%), those pure CTS (49.8 53.4%), respectively Furthermore, cytotoxicity investigation on HepG-2 cell line revealed potential anticancer along good safety margin primary human skin fibroblasts (HSF cells) decent cytocompatibility. Collectively, gained results hypothesized that be effectively applied as promising antibacterial, agent advanced biomedical applications.